Telix Pharmaceuticals Cash Flow Statement 2023-2025 | TLX

Fifteen years of historical annual cash flow statements for Telix Pharmaceuticals (TLX).

Annual Data | Millions of US $ except per share data

Metric Name
Net Income/Loss
Total Depreciation And Amortization - Cash Flow
Other Non-Cash Items
Total Non-Cash Items
Change In Accounts Receivable
Change In Inventories
Change In Accounts Payable
Change In Assets/Liabilities
Total Change In Assets/Liabilities
Cash Flow From Operating Activities
Net Change In Property, Plant, And Equipment
Net Change In Intangible Assets
Net Acquisitions/Divestitures
Net Change In Short-term Investments
Net Change In Long-Term Investments
Net Change In Investments - Total
Investing Activities - Other
Cash Flow From Investing Activities
Net Long-Term Debt
Net Current Debt
Debt Issuance/Retirement Net - Total
Net Common Equity Issued/Repurchased
Net Total Equity Issued/Repurchased
Total Common And Preferred Stock Dividends Paid
Financial Activities - Other
Cash Flow From Financial Activities
Net Cash Flow
Stock-Based Compensation
Common Stock Dividends Paid
20242023
$36.98$2.05
$5.29$4.48
$28.52$31.60
$33.81$36.08
$-37.66$-18.19
$-2.14$-6.40
$28.96$22.39
$-31.57$-20.06
$-42.40$-22.26
$28.39$15.87
$-9.45$-6.43
$-13.00$-0.74
$-20.38$0
$-34.30$-8.74
$0$0
$-34.30$-8.74
$-12.05$-1.02
$-89.17$-16.93
$432$3.82
$-1.33$-1.48
$431$2.35
$0.66$4.42
$0.66$4.42
$0$0
$-9.82$0
$421$6.77
$387$4.59
$12.97$5.84
$0$0